Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock Position Cut by Sphera Funds Management LTD.

Sphera Funds Management LTD. decreased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 4.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 206,251 shares of the company’s stock after selling 9,622 shares during the period. Apellis Pharmaceuticals makes up 1.2% of Sphera Funds Management LTD.’s portfolio, making the stock its 27th biggest position. Sphera Funds Management LTD. owned about 0.17% of Apellis Pharmaceuticals worth $6,581,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Xponance Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 5.6% in the fourth quarter. Xponance Inc. now owns 14,072 shares of the company’s stock valued at $449,000 after acquiring an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in Apellis Pharmaceuticals by 2,707.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after purchasing an additional 758 shares in the last quarter. Signaturefd LLC boosted its stake in Apellis Pharmaceuticals by 357.2% during the 4th quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after purchasing an additional 918 shares in the last quarter. US Bancorp DE increased its position in shares of Apellis Pharmaceuticals by 70.0% during the 4th quarter. US Bancorp DE now owns 3,223 shares of the company’s stock valued at $103,000 after purchasing an additional 1,327 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Apellis Pharmaceuticals by 19.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,615 shares of the company’s stock worth $307,000 after buying an additional 1,578 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Price Performance

NASDAQ APLS opened at $16.36 on Friday. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The firm has a market capitalization of $2.06 billion, a price-to-earnings ratio of -8.06 and a beta of 0.73. The company has a 50 day simple moving average of $20.48 and a 200-day simple moving average of $26.77. Apellis Pharmaceuticals, Inc. has a 52-week low of $16.10 and a 52-week high of $43.99.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). The company had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The company’s revenue was down 3.2% compared to the same quarter last year. During the same period last year, the company posted ($0.54) earnings per share. Equities research analysts predict that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently weighed in on the company. Wedbush decreased their target price on Apellis Pharmaceuticals from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Monday, March 3rd. The Goldman Sachs Group reduced their price objective on shares of Apellis Pharmaceuticals from $36.00 to $32.00 and set a “neutral” rating for the company in a research report on Monday, March 3rd. Mizuho cut their target price on shares of Apellis Pharmaceuticals from $30.00 to $20.00 and set a “neutral” rating for the company in a research note on Wednesday. HC Wainwright restated a “buy” rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Monday, March 3rd. Finally, Bank of America lowered shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $41.00 to $23.00 in a research report on Friday, May 9th. Nine research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $40.42.

Insiders Place Their Bets

In related news, General Counsel David O. Watson sold 5,569 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $25.10, for a total value of $139,781.90. Following the completion of the sale, the general counsel now owns 138,730 shares of the company’s stock, valued at approximately $3,482,123. The trade was a 3.86% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders own 6.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).